Innovation Pharmaceuticals Inc (IPIX)
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company listed on OTC Markets under the symbol IPIX. The company focuses on small-molecule therapies for inflammatory diseases, cancer, dermatology, and anti-infective applications. Its lead candidate, Brilacidin, has been studied for uses including oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Innovation Pharmaceuticals has a license agreement with Alfasigma S.p.A. and a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company, formerly known as Cellceutix Corporation, adopted its current name in June 2017 and was incorporated in 2005. It is headquartered in Wakefield, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-IPIX
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
158.629 K
|